Phase 3 N=48 Major Depressive Disorder With Mixed Features - Extension
Major Depressive Disorder
Primary: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) — 66.7 percentage of subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=211 Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Major Depressive Disorder With Mixed Features
Primary: Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores — -20.5; -13.0 units on a scale — p=<0.0001
Phase 2 N=97 Assessing Symptomatic Clinical Episodes in Depression
Major Depressive Disorder
Primary: MADRS Score - Overall Change From Baseline — 13.7; 8.8 score on a scale — p=<.001
Phase 4 N=41 Iloperidone in Mixed States of Bipolar Disorder
Bipolar Disorder
Primary: Measure of Response by Change From Baseline to End of Study in BISS Depression and Mania Scale Scores — 35.7; 61.8; 25; 48 percentage change in score on BISS scale…
Phase 2 N=73 Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State
Bipolar Disorder · Bipolar Depression · Depression
Primary: The Primary Outcome Measure Was Change in Montgomery-Asberg Depression Rating Scale (MADRS) Scores Over Weeks Between Groups. — 11.4; 5.9 Scores on a scale
Phase 3 N=488 Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
Bipolar Depression · Major Depressive Disorder
Primary: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -18.1; -12.4 score on a scale — p=<0.0001
Phase 4 N=202 A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients
Bipolar I Disorder
Primary: Mean Change in Young Mania Rating Scale (YMRS) Scores From Baseline to Endpoint. — -10.15; -7.68 units on a scale — p=<0.001
Phase 2 N=34 Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation
Severe Mood Dysregulation
Primary: Clinical Global Impression-Severity-Severe Mood Dysregulation — 4.91; 3.62; 4.30; 4.42 units on a scale — p=.58
N/A N=205 Depression Attention for Women Now (The DAWN Study)
Depressive Disorder
Primary: Depression Treatment Outcome — 0.96; 1.33 units on a scale
Phase 4 N=41 Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy
Major Depressive Disorder
Primary: Change in Scores on the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) — 27.5; 29; 22.6; 25 Scores on a scale
Phase 2 N=53 A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation
Mood Disorder · Mental Disorder Diagnosed in Childhood · Attention Deficit and Disruptive Behavior Disorder
Primary: Percentage of Participants That "Much Improved" (Score of 2) in, or "Completely Recovered" (Score of 1) From Their Irritability Severity, as Measured With the Clinical…
Phase 2 N=204 Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
Major Depressive Disorder
Primary: Change From Baseline in Hamilton Depression Rating Scale (HAMD-17) Total Score at Weeks 8 — -9.0; -7.4 Scores on a scale — p=0.121
Phase 4 N=665 Combining Medications to Enhance Depression Outcomes
Major Depressive Disorder
Primary: Quick Inventory of Depressive Symptoms — 46.6; 41.8; 46.0 percentage of participants
Phase 4 N=30 Duloxetine Treatment in Elderly With Dysthymia
Depression · Dysthymic Disorder
Primary: Change in Hamilton Rating Scale for Depression (HAM-D, 24-item) From 0 Weeks to 12 Weeks. — 8 units on a scale — p=<0.001
Phase 3 N=327 A Trial of AXS-05 in Patients With Major Depressive Disorder
Depression · Major Depressive Disorder
Primary: Change in MADRS Total Score From Baseline to Week 6 — 15.91; 12.04 score on a scale — p=0.002
Phase 4 N=107 Cost- Effectiveness and Quality of Life Assessment in Mood Disorder
Bipolar Disorder
Primary: Number of Participants With Response to Treatment" — 31; 28; 27 Participants
Phase 3 N=513 A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Depressive Disorder, Major · Anhedonia
Primary: Change From Baseline to Day 43 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -11.4; -12.3 Units on a scale — p==0.467
Phase 3 N=337 A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint — -24.3; -23.7; -24.3 units on a scale — p=0.999
Phase 3 N=480 Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Montgomery-Asberg Depression Rating Scale — -14.7; -10.2 units on a scale — p=<0.0001
Phase 2 N=7 Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial
Major Depressive Disorder · Alcohol Use Disorder
Primary: Drinks Per Drinking Day — 2.8; 2.0 Drinks per drinking day
Phase 3 N=463 A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint — -23.9; -21.6 units on a scale — p=0.193
Phase 4 N=28 Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder
Bipolar Disorder
Primary: Number of Patients Whose Mood Improved According to MADRS and YMRS Scale Scores. — 4; 4; 4; 4 participants
Phase 4 N=65 Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression
Bipolar Depression
Primary: Response to Treatment — 21; 9; 6; 11 Participants — p=.02
Phase 3 N=1,149 A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Phase C: Time-to-Relapse by Any Criteria as Defined in Blinded Addendum — 63.0; 63.0 days — p=0.5100
N/A N=386 Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline to Week 6 in the MADRS Total Score — -9.03; -7.25 score on a scale — p=0.0568
N/A N=36 iCBT With TMS in Patients With MDD
Major Depressive Disorder
Primary: Hamilton Depression Rating Scale (HAM-D) — 20.4375; 21.7692; 11.3333; 11.9231 score on a scale
Phase 4 N=21 Brexpiprazole for Bipolar Depression
Bipolar Depression
Primary: The Montgomery-Asberg Depression Rating Scale (MADRS) — 31.95; 9.95; 10.95 score on a scale — p=<.001
Phase 2 N=296 Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression
Depression
Primary: Hamilton Rating Scale for Depression — 11.06; 12.52 units on a scale
Phase 3 N=444 A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Depressive Disorder, Major · Anhedonia
Primary: Change From Baseline to Day 43 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.4; -10.0 Units on a scale — p==0.670
Phase 3 N=349 A Study of Aripiprazole in Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Mean Change in the Montgomery Åsberg Depression Rating Scale (MADRS) — -10.12; -6.39 units on a scale — p=<0.001